MLXIPL and metabolic dysfunction-associated steatotic liver disease: Once in the liver, FFAs and cytokines activate transcription factors such as sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate response element-binding protein (ChREBP), promoting de novo lipogenesis and triglyceride synthesis, thus leading to the progression of MASLD [51,69].